Section Arrow
BLTE.NASDAQ
- Belite Bio
Quotes are at least 15-min delayed:2024/05/16 04:12 EDT
Last
 42.45
+0.45 (+1.07%)
Day High 
42.56 
Prev. Close
42 
1-M High
43.45 
Volume 
36.50K 
Bid
16.98
Ask
43.85
Day Low
40.09 
Open
42 
1-M Low
31.005 
Market Cap 
1.25B 
Currency USD 
P/E -- 
%Yield
10-SMA 42.29 
20-SMA 39.56 
50-SMA 40.42 
52-W High 48.6 
52-W Low 11 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.19/-0.86
Enterprise Value
1.25B
Balance Sheet
Book Value Per Share
3.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 04:12 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.